BridgeBio Pharma, Inc. (BBIO) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, BridgeBio Pharma, Inc.'s filing signal turned positive.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic diseases, leveraging a decentralized hub-and-spoke model to advance multiple programs efficiently. The company has achieved FDA approval for its commercial product, Attruby (acoramidis), for transthyretin amyloid cardiomyopathy (ATTR-CM), generating $362.4 million in U.S. net product revenues in 2025. It also has a pipeline of late-stage product candidates, including infigratinib for achondroplasia, encaleret for autosomal dominant hypocalcemia type 1, and BBP-418 for limb-girdle muscular dystrophy type 2I/R9, with regulatory submissions planned for 2026. BridgeBio operates globally, with Attruby marketed as Beyonttra outside the U.S. through partnerships with Bayer in Europe and Alexion in Japan.

Primary revenue drivers include net product sales from Attruby (acoramidis) in the U.S. and license and royalty revenue from Beyonttra (acoramidis) sales in Europe and Japan through collaboration partners.